KPRX Stock Earnings: Kiora Pharmaceuticals Beats EPS for Q2 2024

Written by Emily J. Thompson, Senior Investment Analyst

KPRX+4.35%

Source: Business Insider

Updated: Aug 09 2024

0mins

Source: Business Insider

Kiora Pharmaceuticals Q2 2024 Results: Kiora Pharmaceuticals reported a second quarter earnings per share of -53 cents, surpassing the analyst estimate of -81 cents, with total revenue of $20,000.
InvestorPlace Earnings Automation: InvestorPlace Earnings utilizes automated data from TradeSmith to quickly publish key financial metrics and comparisons to analyst estimates for quarterly earnings reports.

Trade with 70% Backtested Accuracy

Stop guessing "Should I Buy KPRX?" and start using high-conviction signals backed by rigorous historical data.

Sign up today to access powerful investing tools and make smarter, data-driven decisions.

KPRX

$2.4+Infinity%1D

Analyst Views on KPRX

Wall Street analysts forecast KPRX stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for KPRX is 12.00 USD with a low forecast of 12.00 USD and a high forecast of 12.00 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.

1 Analyst Rating

1 Buy

0 Hold

0 Sell

Moderate Buy

Current: 2.300

Low

12.00

Averages

12.00

High

12.00

Current: 2.300

Low

12.00

Averages

12.00

High

12.00

H.C. Wainwright

Buy

maintain

$10

2025-07-22

Reason

H.C. Wainwright

Price Target

$10

AI Analysis

2025-07-22

maintain

Buy

Reason

H.C. Wainwright reiterates a Buy rating and $10 price target on shares of Kiora Pharmaceuticals after the company announced that it received received a U.S. patent covering KIO-104 for the treatment of ocular diseases, including ocular inflammation, uveitis, age-related macular degeneration, and complications from refractive surgery. The patent covers varying dosing schedules, necessary excipients, and other novel methods for optimizing treatment of ocular inflammatory diseases, the analyst tells investors in a research note. The new patent should strengthen the company's IP portfolio and help secure the potential market prospects if KIO-104 is successfully developed in clinical studies, the firm says.

HC Wainwright & Co.

Yi Chen

Strong Buy

Reiterates

$10

2025-03-28

Reason

HC Wainwright & Co.

Yi Chen

Price Target

$10

2025-03-28

Reiterates

Strong Buy

Reason

About KPRX

Kiora Pharmaceuticals, Inc. is a clinical-stage pharmaceutical company, which is engaged in developing and commercializing therapies for the treatment of retinal diseases. The Company is engaged in developing KIO-301, a vision-restoring small molecule that acts as a photoswitch specifically created to restore vision in patients with inherited and age-related degenerative retinal diseases, including retinitis pigmentosa (RP). It is also developing KIO-104 for the treatment of retinal inflammatory diseases, including Diabetic Macular Edema (DME) and Posterior Non-Infectious Uveitis, a rare T cell-mediated, intraocular inflammatory disease. KIO-104 is a non-steroidal small-molecule inhibitor of dihydroorotate dehydrogenase (DHODH) formulated for intravitreal delivery and is ideally suited to suppressing overactive T-cell activity to treat the underlying inflammation. KIO-101 focuses on treating the ocular manifestation of patients with autoimmune diseases.

About the author

Emily J. Thompson

Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.

GET FREE REAL TIME NOTIFICATIONS

Stock Monitor for KPRX?

Get Started Free

FREE STOCK RECOMMENDATIONS DAILY

Stock Bullish Tomorrow

Get Started Free

70% BACKTESTED ACCURACY!

Should I Buy KPRX?

Get Started Free

Top News

KPRX Stock Earnings: Kiora Pharmaceuticals Beats EPS for Q2 2024

Trade with 70% Backtested Accuracy

Analyst Views on KPRX

About KPRX

About the author

Top News

Oil Firms Cautious on Venezuela Investment Push

GM Reports $7.1 Billion Charge Amid EV Shift

Stock Market Wraps 2025 with Double-Digit Gains

Novo Nordisk's Weight-Loss Pill Approval: Key Impacts

Related Articles

Nvidia's Stock Volatility and Growth Potential

Nvidia Stock Predictions: Bullish and Bearish Analyst Insights

Kiora Pharmaceuticals Joins RARE-X Vision Consortium Promoting Collaboration and Development of New Treatments for Rare Ocular Disorders

HC Wainwright & Co. Reiterates Buy on Kiora Pharmaceuticals, Maintains $10 Price Target

Sigh Up to Get Intellectia Insights

How did the company's recent strategic decisions impact its latest financial performance?

Can you explain the factors behind the recent changes in the company's stock price?

What are the expected impacts of current market trends on the company's future growth?

Based on the latest earnings report, what are the company's forecasted revenues for the next quarter?

How does the company's performance compare to its main competitors in the same sector?

People Also Watch